Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.53 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.44 |
| ▸ | LIPE | Q05469 | 2/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.40 |
| ▸ | DPP4 | P27487 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2879399 | 1.00 | USP30 (0.53) | USP30NR1H2HDAC1HDAC2LIPE | |
| SCHEMBL5262963 | 0.85 | USP30 (0.42) | USP30HDAC1HDAC2LIPEGPR119 | |
| SCHEMBL2884981 | 0.82 | GPR119 (0.52) | USP30NR1H2LIPEGPR119HRH3 | |
| SCHEMBL27405003 | 0.82 | HDAC1 (0.49) | USP30NR1H2HDAC1HDAC2LIPE | |
| SCHEMBL27405008 | 0.82 | HDAC1 (0.49) | USP30NR1H2HDAC1HDAC2LIPE | |
| SCHEMBL23783164 | 0.81 | GPR119 (0.58) | NR1H2GPR119SMN1; SMN2 | |
| SCHEMBL16570116 | 0.81 | SMARCA2 (0.56) | NR1H2GPR119SMN1; SMN2HRH3 | |
| SCHEMBL13419754 | 0.81 | SMARCA2 (0.56) | NR1H2GPR119SMN1; SMN2HRH3 | |
| SCHEMBL30890364 | 0.79 | NR1H2 (0.46) | USP30NR1H2HDAC1HDAC2GPR119 | |
| SCHEMBL18488357 | 0.79 | USP30 (0.52) | USP30NR1H2HDAC1HDAC2LIPE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8828991-B2 | Azacyclyl-substituted arylthienopyrimidinones, process for their preparation and their use as medicaments | SANOFI (FR) | 2014-09-09 | — | — | US | disclosed |
| US-20090082339-A1 | NOVEL AZACYCLYL-SUBSTITUTED ARYLTHIENOPYRIMIDINONES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | SANOFI-AVENTIS (FR) | 2009-03-26 | — | — | US | disclosed |
| EP-1986646-A1 | NOVEL AZACYCLY-SUBSTITUTED ARYLTHIENOPYRIMIDINONES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | Sanofi-Aventis (FR) | 2008-11-05 | — | — | EP | disclosed |
| WO-2007093363-A1 | NOVEL AZACYCLY-SUBSTITUTED ARYLTHIENOPYRIMIDINONES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | SANOFI-AVENTIS (DE) | 2007-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082339-A1 | NOVEL AZACYCLYL-SUBSTITUTED ARYLTHIENOPYRIMIDINONES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | MCHR1, MPI, TPMT | USP30 1108/4885NR1H2 2498/4885HDAC1 3993/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.